Cargando…

Downregulation of LINC01140 is associated with adverse features of breast cancer

Breast cancer (BC) is one of the most dangerous malignant diseases among women. A growing amount of evidence has suggested that long non-coding RNAs participate in the development and progression of BC and may potentially serve as therapeutic targets or prognostic markers for the disease. A previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Deheng, Li, Liangdong, Cao, Yiqun, Chen, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955654/
https://www.ncbi.nlm.nih.gov/pubmed/31966045
http://dx.doi.org/10.3892/ol.2019.11147
_version_ 1783486977669070848
author Li, Deheng
Li, Liangdong
Cao, Yiqun
Chen, Xin
author_facet Li, Deheng
Li, Liangdong
Cao, Yiqun
Chen, Xin
author_sort Li, Deheng
collection PubMed
description Breast cancer (BC) is one of the most dangerous malignant diseases among women. A growing amount of evidence has suggested that long non-coding RNAs participate in the development and progression of BC and may potentially serve as therapeutic targets or prognostic markers for the disease. A previous study demonstrated that long intergenic non-protein coding RNA 01140 (LINC01140) was prominently correlated with overall survival in patients with gastric cancer. However, the function of LINC01140 in BC has not yet been elucidated. Therefore, the present study aimed to investigate the roles and molecular mechanisms underlying LINC01140 in BC. LINC01140 expression in 1,085 breast cancer patients and 291 healthy subjects was analyzed from the Gene Expression Profiling Interactive Analysis website. The association between LINC01140 expression and T stages, LINC01140-related biological pathways, and the correlation between LINC01140 expression genes were also analyzed in 825 patients with BC through the cBioPortal database. The present study demonstrated that LINC01140 expression was significantly decreased in the tumor samples compared with normal samples in patients with BC (P<0.05). The present study revealed that LINC01140 expression was significantly decreased in the T4 stage compared with T1, T2 or T3 stage (P<0.01). In addition, high expression levels of LINC01140 predicts longer relapse-free survival probability in patients with BC. It was also observed that LINC01140 participates in a variety of biological pathways, particularly in the epithelial-to-mesenchymal transition. The co-expression relationship between the LINC01140 and an abundance of genes in samples from the BC study was investigated. These genes, such as chordin like 1 and bone morphogenic protein 6, participate in the development and progression of tumor growth and bone metastasis. Finally, the present study observed the interaction between microRNA (miR)-200b and miR-200c with LINC011440. The results from the present study indicated that higher expression of LINC01140 was beneficial for patients with BC. LINC01140 may be a potential biomarker for the prognosis of patients with BC. The role of LINC01140 in BC needs to be further evaluated.
format Online
Article
Text
id pubmed-6955654
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-69556542020-01-21 Downregulation of LINC01140 is associated with adverse features of breast cancer Li, Deheng Li, Liangdong Cao, Yiqun Chen, Xin Oncol Lett Articles Breast cancer (BC) is one of the most dangerous malignant diseases among women. A growing amount of evidence has suggested that long non-coding RNAs participate in the development and progression of BC and may potentially serve as therapeutic targets or prognostic markers for the disease. A previous study demonstrated that long intergenic non-protein coding RNA 01140 (LINC01140) was prominently correlated with overall survival in patients with gastric cancer. However, the function of LINC01140 in BC has not yet been elucidated. Therefore, the present study aimed to investigate the roles and molecular mechanisms underlying LINC01140 in BC. LINC01140 expression in 1,085 breast cancer patients and 291 healthy subjects was analyzed from the Gene Expression Profiling Interactive Analysis website. The association between LINC01140 expression and T stages, LINC01140-related biological pathways, and the correlation between LINC01140 expression genes were also analyzed in 825 patients with BC through the cBioPortal database. The present study demonstrated that LINC01140 expression was significantly decreased in the tumor samples compared with normal samples in patients with BC (P<0.05). The present study revealed that LINC01140 expression was significantly decreased in the T4 stage compared with T1, T2 or T3 stage (P<0.01). In addition, high expression levels of LINC01140 predicts longer relapse-free survival probability in patients with BC. It was also observed that LINC01140 participates in a variety of biological pathways, particularly in the epithelial-to-mesenchymal transition. The co-expression relationship between the LINC01140 and an abundance of genes in samples from the BC study was investigated. These genes, such as chordin like 1 and bone morphogenic protein 6, participate in the development and progression of tumor growth and bone metastasis. Finally, the present study observed the interaction between microRNA (miR)-200b and miR-200c with LINC011440. The results from the present study indicated that higher expression of LINC01140 was beneficial for patients with BC. LINC01140 may be a potential biomarker for the prognosis of patients with BC. The role of LINC01140 in BC needs to be further evaluated. D.A. Spandidos 2020-02 2019-11-25 /pmc/articles/PMC6955654/ /pubmed/31966045 http://dx.doi.org/10.3892/ol.2019.11147 Text en Copyright: © Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Li, Deheng
Li, Liangdong
Cao, Yiqun
Chen, Xin
Downregulation of LINC01140 is associated with adverse features of breast cancer
title Downregulation of LINC01140 is associated with adverse features of breast cancer
title_full Downregulation of LINC01140 is associated with adverse features of breast cancer
title_fullStr Downregulation of LINC01140 is associated with adverse features of breast cancer
title_full_unstemmed Downregulation of LINC01140 is associated with adverse features of breast cancer
title_short Downregulation of LINC01140 is associated with adverse features of breast cancer
title_sort downregulation of linc01140 is associated with adverse features of breast cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955654/
https://www.ncbi.nlm.nih.gov/pubmed/31966045
http://dx.doi.org/10.3892/ol.2019.11147
work_keys_str_mv AT lideheng downregulationoflinc01140isassociatedwithadversefeaturesofbreastcancer
AT liliangdong downregulationoflinc01140isassociatedwithadversefeaturesofbreastcancer
AT caoyiqun downregulationoflinc01140isassociatedwithadversefeaturesofbreastcancer
AT chenxin downregulationoflinc01140isassociatedwithadversefeaturesofbreastcancer